Plataforma de Laboratorio, Hospital General Universitario Gregorio Marañón, C/Doctor Esquerdo 46, Madrid, Spain.
BioDrugs. 2010 Oct 1;24(5):331-43. doi: 10.2165/11538400-000000000-00000.
HIV infection of the CNS is the principle cause of HIV-associated dementia in adults and encephalopathy in children. Gene therapy techniques such as small interfering RNA (siRNA) possess great potential in drug development, but first they must overcome the key obstacle of reaching the interior of the affected cells. A successful delivery vector for anti-HIV drugs that is capable of crossing the blood-brain barrier (BBB) could provide a way of addressing this issue. Non-viral vectors such as dendrimers offer a means for effectively delivering and transfecting siRNA to the target cells.
To evaluate the application of gene therapy for reducing HIV replication in human astrocytes.
We used the 2G-NN16 amino-terminated carbosilane dendrimer as a method for delivering siRNA to HIV-infected human astrocytes. We tested the cytotoxicity in human astrocytoma cells caused by 2G-NN16 and dendriplexes formed with siRNA (siRNA/2G-NN16) by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium-bromide (MTT) and lactate dehydrogenase assays. The ability to transfect human astrocytes with siRNA/2G-NN16 dendriplexes was tested by flow cytometry and immunofluorescence microscopy. To assess the potential capability of siRNA/2G-NN16 dendriplexes for crossing the BBB, we used an in vitro transcytosis assay with bovine brain microvascular endothelial cells. HIV-1 inhibition assays using 2G-NN16 and siRNA/2G-NN16 dendriplexes were determined by quantification of the viral load from culture supernatants of the astrocytes.
A gradual time-controlled degradation of the 2G-NN16 dendrimer and liberation of its siRNA cargo between 12 and 24 hours was observed via gel electrophoresis. There was no cytotoxicity in HIV-infected or non-infected human astrocytoma cells when treated with up to 24 microg/mL of 2G-NN16 dendrimer or siRNA/2G-NN16 dendriplexes, and siRNA/2G-NN16 dendriplexes were seen to successfully transfect human astrocytes even after crossing an in vitro BBB model. More interestingly, transfected siRNA was observed to exert a biologic effect, as dendriplexes were shown to down-regulate the housekeeping gene GAPDH and to reduce replication of HIV-1 strains X4-HIV NL4-3 and R5-HIV BaL in human astrocytes.
The 2G-NN16 dendrimer successfully delivers and transfects siRNA to HIV-infected human astrocytes and achieves gene silencing without causing cytotoxicity.
HIV 对中枢神经系统的感染是导致成人 HIV 相关性痴呆和儿童脑病的主要原因。基因治疗技术,如小干扰 RNA(siRNA),在药物开发方面具有巨大的潜力,但首先必须克服到达受影响细胞内部的关键障碍。一种能够穿透血脑屏障(BBB)的抗 HIV 药物的有效递药载体,可以为解决这一问题提供一种方法。树状聚合物等非病毒载体为有效递送和转染 siRNA 至靶细胞提供了一种手段。
评估基因治疗降低人星形胶质细胞中 HIV 复制的应用。
我们使用 2G-NN16 端氨基碳硅烷树状聚合物作为将 siRNA 递送至 HIV 感染的人星形胶质细胞的方法。我们通过 3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四唑溴化物(MTT)和乳酸脱氢酶测定法,检测 2G-NN16 和与 siRNA 形成的树状聚合物(siRNA/2G-NN16)对人星形胶质细胞瘤细胞的细胞毒性。通过流式细胞术和免疫荧光显微镜检测 siRNA/2G-NN16 树状聚合物转染人星形胶质细胞的能力。为了评估 siRNA/2G-NN16 树状聚合物穿过 BBB 的潜在能力,我们使用体外转胞吞测定法,用牛脑微血管内皮细胞进行实验。通过测定星形胶质细胞培养上清液中的病毒载量,确定 2G-NN16 和 siRNA/2G-NN16 树状聚合物的 HIV-1 抑制试验。
通过凝胶电泳观察到,2G-NN16 树突状聚合物在 12 至 24 小时之间逐渐进行时间控制的降解,释放其 siRNA 货物。用高达 24 μg/mL 的 2G-NN16 树突状聚合物或 siRNA/2G-NN16 树状聚合物处理 HIV 感染或未感染的人星形胶质细胞瘤细胞时,均无细胞毒性,并且即使在穿过体外 BBB 模型后,siRNA/2G-NN16 树状聚合物也能够成功转染人星形胶质细胞。更有趣的是,转染的 siRNA 发挥了生物学作用,因为树状聚合物被证明下调管家基因 GAPDH,并减少 HIV-1 株 X4-HIV NL4-3 和 R5-HIV BaL 在人星形胶质细胞中的复制。
2G-NN16 树突状聚合物成功地将 siRNA 递送至 HIV 感染的人星形胶质细胞并进行转染,且不会引起细胞毒性,实现基因沉默。